Pustular psoriasis

This phase 3 trial tests the drug TAK-279 in 18 adults with generalized pustular psoriasis or erythrodermic psoriasis, two rare and severe forms of the disease. All participants receive the drug for up to 52 weeks to see if it clears skin symptoms and is safe. The study is open-l…

This Phase 3 trial tested a drug called imsidolimab in 45 adults with generalized pustular psoriasis (GPP), a rare and severe skin condition that causes painful pustules. Participants received either a single intravenous dose of imsidolimab (750 mg or 300 mg) or a placebo. The ma…

This study tested a higher dose (10 mg/kg every 8 weeks) of the drug TA-650 in 51 adults with psoriasis who had initially improved on the standard dose of Remicade but later lost that benefit. The goal was to see if the increased dose could again reduce skin symptoms. Participant…

This study monitored 52 Japanese patients with generalized pustular psoriasis (GPP) who received spesolimab for acute symptoms. Researchers tracked side effects and disease activity in everyday clinical settings, not a controlled lab environment. The goal was to see how well the …

This program in China gave a single infusion of spesolimab to 39 people with a severe skin condition called generalized pustular psoriasis (GPP) during a flare-up. Participants had no other treatment options available. The goal was to control the flare and monitor for side effect…

This study tested four different doses of an experimental drug (BI 655130) against a placebo in 152 adults with moderate to severe palmoplantar pustulosis (PPP), a skin condition causing painful pus-filled blisters on the palms and soles. The main goal was to see which dose best …

This study tested a drug called spesolimab in 59 people with palmoplantar pustulosis (PPP), a painful skin condition causing pustules and plaques on the palms and soles. Participants received either low or high doses of spesolimab or a placebo for 12 weeks. The goal was to see if…

This study tested a single dose of spesolimab in 53 people with generalized pustular psoriasis (GPP) experiencing a moderate-to-severe flare. The drug aims to quickly clear skin pustules. Results showed that more patients receiving spesolimab had no visible pustules after one wee…

This study tested a drug called imsidolimab in 8 adults with generalized pustular psoriasis (GPP), a rare and severe skin condition. The drug is an antibody that targets inflammation. Researchers measured how well it worked using skin scores and other health markers. The goal was…

This phase 2 trial tested a monthly injection called imsidolimab (ANB019) in 59 adults with palmoplantar pustulosis, a chronic skin condition causing painful, pus-filled blisters on the palms and soles. The study compared the drug to a placebo to see if it could reduce the severi…

This study tested whether an artificial intelligence (AI) tool could help primary care doctors diagnose skin conditions more accurately. Nine doctors reviewed 30 images of various skin problems, first giving their own diagnosis and then a final diagnosis after seeing the AI's sug…

This study tested whether a monthly injection of spesolimab can prevent flare-ups of generalized pustular psoriasis (GPP), a rare and severe skin condition. 123 people aged 12 to 75 with clear or nearly clear skin joined the trial. They received either one of three doses of speso…

This study tested whether an artificial intelligence (AI) tool could help doctors diagnose rare and tricky skin conditions like generalized pustular psoriasis (GPP). Fifteen doctors, including both general practitioners and dermatologists, looked at 100 skin images. They first ga…

This completed registry study in Japan looked at how doctors treat palmoplantar pustulosis (PPP), a skin condition causing pus-filled blisters on hands and feet. Researchers collected data from 276 patients' medical records and clinic visits to understand which treatments are use…